Pfizer commits $4M to NC Biotechnology Center gene therapy fellowship program – WRAL Tech Wire
|
Pfizer commits $4M to NC Biotechnology Center gene therapy fellowship program
WRAL Tech Wire With that acquisition, Pfizer gained the expertise of Bamboo’s world-renowned co-founder, R. Jude Samulski, Ph.D., director of the Gene Therapy Center at the University of North Carolina at Chapel Hill. The deal also included an 11,000-square-foot … |
Telegraph.co.uk |
Gene Therapy Shows Promise for Aggressive Lymphoma
WebMD TUESDAY, Feb. 28, 2017 (HealthDay News) — An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy’s developers report. Thirty-six percent of over 100 very ill … Terminal cancer patients in complete remission after one gene therapy treatmentTelegraph.co.uk Gene therapy leaves terminal cancer patients in complete remissionWND.com New gene therapy ‘shrinks tumours like ice cubes’The Times (subscription) Kite Pharma, Inc. | Investor Relations all 273 news articles » |
CTV News |
More stem cell donors needed to save lives in Sask.
CTV News Lincoln Honoway found his match in time, but others aren’t so lucky. More than 800 Canadians are currently waiting for an unrelated stem cell donor. Only one in two find a match. One year ago, Lincoln was admitted to hospital with dangerously low blood … |
|
Gene Therapy Shows Promise for Aggressive Lymphoma
HealthDay TUESDAY, Feb. 28, 2017 (HealthDay News) — An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy’s developers report. Thirty-six percent of over 100 very ill … |
|
Sarcoma: Evaluation of Immunotherapy Using Dendritic Cells
Cancer Therapy Advisor Dendritic cell–based immunotherapy does not improve outcomes for patients with refractory sarcoma, according to the results of a phase 1/2 study published in Cancer.1. Relapsed sarcomas are often unresponsive to chemotherapy, limiting treatment options … |
Melanoma News Today |
Gut Bacteria Composition May Determine Melanoma Patients’ Response to Anti-PD-1 Immunotherapy
Melanoma News Today The presence of a specific bacteria in the gut of patients with melanoma, as well as a greater diversity of gut bacteria, are associated with a better response to anti-PD-1 immunotherapy. Understanding this relationship between a patient’s gut bacteria … |